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Aplidine, dehydrodidemnin B, is a marine depsipeptide isolated from the Mediterranean tunicate Aplidium albicans currently in
phase II clinical trial. In human Molt-4 leukaemia cells Aplidine was found to be cytotoxic at nanomolar concentrations and to
induce both a G1 arrest and a G2 blockade. The drug-induced cell cycle perturbations and subsequent cell death do not
appear to be related to macromolecular synthesis (protein, RNA, DNA) since the effects occur at concentrations (e.g. 10 nM)
in which macromolecule synthesis was not markedly affected. Ten nM Aplidine for 1 h inhibited ornithine decarboxylase
activity, with a subsequently strong decrease in putrescine levels. This ﬁnding has questionable relevance since addition of
putrescine did not signiﬁcantly reduce the cell cycle perturbations or the cytotoxicity of Aplidine. The cell cycle perturbations
caused by Aplidine were also not due to an effect on the cyclin-dependent kinases. Although the mechanism of action of
Aplidine is still unclear, the cell cycle phase perturbations and the rapid induction of apoptosis in Molt-4 cells appear to be due
to a mechanism different from that of known anticancer drugs.
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Aplidine, dehydrodidemnin B (Figure 1, chemical structure), is a
marine depsipeptide isolated from the Mediterranean tunicate Apli-
dium albicans, that is structurally related to didemnin B, and has
been shown to be in vitro active against both human haematho-
logical and solid tumour cell lines (Urdiales et al, 1996; Lobo et
al, 1997; Depenbrock et al, 1998; Geldof et al, 1999), Moreover,
Aplidine has been shown to be active against in vivo murine B16
melanoma and in several human tumours growing in athymic mice
(Faircloth et al, 1995, 1996).
It has been described that didemnins inhibit the progression
from G1 to S phase of the cell cycle (Crampton et al, 1984). Several
biochemical effects of didemnins have also been reported: inhibi-
tion of protein synthesis via GTP-dependent elongation factor 1-
alpha in vitro (Crews et al, 1994), and of protein, DNA and
RNA syntheses in different cell lines (Crampton et al, 1984; Sakai
et al, 1996) Inhibition of the ornithine decarboxylase (ODC)
activity by didemnins was previously described (Urdiales et al,
1996), but the relevance of this biochemical effect for the antitu-
mour activity of Aplidine has not been shown.
The present study purpose is to better characterise the mechan-
isms involved in the Aplidine-induced antiproliferative effect, cell
cycle perturbations and cell death induced in human Molt-4
leukaemia cell line.
MATERIALS AND METHODS
Drug treatment
Aplidine (Figure 1) was generously provided by PharmaMar. The
cytotoxic effect of Aplidine on Molt-4 cells was evaluated by expos-
ing the cells for different times to the drug and by counting the
number of cells at different time intervals after drug-washout by
a Coulter Counter instrument.
Cell cycle
Monoparametric DNA analysis and cell ﬂux simulation Ex-
ponentially growing Molt-4 cells were treated for 1 h with 0, 1,
5, 10, 20 or 30 nM Aplidine. At 24, 48 and 72 h after drug-washout
the number of cells was evaluated by counting the cells with a
Coulter Counter instrument, and the cells were ﬁxed in 70% etha-
nol and kept at 48C before DNA staining with propidium iodide.
DNA ﬂow cytometric analysis were performed on at least
10000 cells using a FACSCalibur system (Becton Dickinson,
Sunnyvale, CA, USA). The coefﬁcient of variation of the G1 peak
of the Molt-4 ﬁxed cells was between 2 and 2.5%. The DNA histo-
grams of each sample were analysed and the percentages of cells in
each cell cycle phase were derived by means of a home-made ﬁtting
programme based on the sum-of-gaussians method (Ubezio, 1985;
Sena et al, 1999). However the direct analysis of the experimental
data expressed as percentage of cells in a given phase can be
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www.bjcancer.commisleading if there is a concomitant cell cycle block with killing in
one or different phases of the cell cycle. In fact if the drug kills in
one phase and blocks in the same phase the percentage of cells in
that phase might be similar to that of untreated control cells. This
is explained by the fact that a cell killing effect results in a decrease
of the percentage and the block is a relative increase in that percen-
tage. The relative importance of the two effects, i.e. blocking and
cell killing can vary overtime making the interpretation of the data
virtually impossible. In addition when the block is overcome there
might be a wave of synchronisation with changes in the relative
distribution of cells in the different phases compared to asynchro-
nous cell cycle distribution of control cells.
In order to overcome these interpretation problems we have
developed and used a simulation programme, previously described
in detail (Montalenti et al, 1998; Sena et al, 1999), based on the
kinetic properties of the cell line.
The simulation programme forecasts the cell cycle ﬂux in a cell
population, starting from the cell cycle distribution at a given time
hypothesising the probability that a cell is blocked or killed in a cell
cycle phase. The time-course of cell counts and of %G1, %S and
%G2M are given as output and can be compared with actual data.
Thus, the programme enables us to test a hypothesis on the
time-course of blocking and killing that can occur in each phase
to correlate with the data. The latest version of the programme
runs on a personal computer using Microsoft Excel and is available
from the author (ubezio@marionegri.it).
Biparametric BrdUrd/DNA analysis During the last 15 min of
1 h Aplidine exposure, 20 mM bromodeoxyuridine (BrdUrd) was
added to the cells. After treatment the cells were washed twice with
PBS and fresh medium was provided. After 1 h treatment and at 4,
8, 12, 24, 29, 36 and 48 h after drug-washout control and treated
cells were ﬁxed in 70% ethanol and kept at 48C before BrdUrd/
DNA ﬂow cytometric analysis (Erba et al, 2001). With this protocol
it was also possible to obtain a distinct evaluation of cell cycle
perturbations in cells which were in S phase (BrdUrd positive cells)
or in G1 or in G1M phases (BrdUrd negative cells) during 1 h
10 nM Aplidine exposure.
Ornithine decarboxylase (ODC) activity assay
Frozen cells (5610
6) were sonicated in 100 ml of cold Tris-HCl
(pH 7.2) containing 0.1 mM EDTA and 2 mM DTT and were
subsequently centrifuged at 14000 r.p.m. for 20 min in an Eppen-
dorf microcentrifuge at 48C. ODC activity was measured in the
supernatants as release of labelled CO2 from [1-
14C]ornithine
(56 Ci mol
71, Amersham Pharmacia Biotech, Milan, Italy), as
previously reported (Desiderio et al, 1993). The reaction mixture
(ﬁnal volume 250 ml) contained cytosol supernatant (about
150 mg of protein), 50 mM Tris-HCl (pH 7.1), and 1 mM
[1-
14C]ornithine (sp. act. 4 Ci mol
71). Blanks were prepared in
the presence of 4 mM a-diﬂuoromethylornithine (generously given
by Marion Merrell Dow Research Institute, Strasbourg, France) to
inhibit ODC activity. ODC activity is reported as pmol of CO2
formed in 1 h per mg of protein. Protein content in cytosol
extracts was assayed by the standard method (Lowry et al, 1951).
Polyamine determination
Frozen cell samples (3610
6) were sonicated in 80 ml of 0.2 N PCA
and then centrifuged at 5000 r.p.m. in an Eppendorf microcentri-
fuge for 20 min. Aliquots of supernatants were analysed by
HPLC (Perkin-Elmer Corp., Norwalk, CN, USA) using a C18
reverse-phase column (4 mm particle size, 15063.9 mm, Waters).
Evaluation of polyamines was performed after post-column deriva-
tisation with o-phtaldialdehyde and ﬂuorescence detection
(Desiderio, 1992).
DNA, RNA and proteins synthesis assay
Exponentially growing cells were treated with different concentra-
tions of Aplidine. At different drug exposure time intervals
1 mCi ml
71 [
3H]thymidine, or 1 mCi ml
71 [
3H]uridine, or
2 mCi ml
71 [
3H]leucine were added to the cells for 2 h and the
radioactivity was evaluated by using a liquid scintillator counter.
Extracts preparation, Western blotting analysis and
CDK activity
Cell extracts were prepared by addition of lysis buffer containing
protease inhibitors according to standard procedures (Sambrook
et al, 1989). Extracts corresponding to 100 mg of protein were
separated on 12% SDS–PAGE, blotted onto nitrocellulose
membranes, and incubated with antibodies against cyclins B, D1
and E, Cdk2, Cdk4, Cdc2, p21, p16, p53, pRb, Bax and Caspase
3 (Santa Cruz Biotech.,Inc., Heidelberg, Germany). As secondary
antibodies, horseradish peroxidase labelled anti-rabbit or anti-
mouse antibodies (Santa Cruz Biotech) were used. Protein bands
were visualised by enhanced chemiluminescence. Kinase activity
was measured as previously reported (Bonfanti et al, 1997)
Detection of apoptotic process
The fraction of apoptotic cells after Aplidine exposure was evalu-
ated by Terminal-dUTP-Transferase (TdT) ﬂow cytometric assay
as previously described (Bergamaschi et al, 1999).
RESULTS
Growth inhibition
Aplidine was active at nanomolar concentrations, which induced a
dose-dependent growth inhibition in Molt-4 cells (Figure 2) and
the effects appeared to be similar at 1 h (A) and 24 h treatment
time (B).
Cell cycle studies
We were interested in evaluating the drug’s effects on G1, S and
G2M phases separately to distinguish blocking or delaying effects
from killing ones. Figure 3 shows the experimental percentages
of G1 and G2M at different times after Aplidine treatment,
compared to the amount of blocked or lost cells resulting from
the simulation. The computer simulation allowed us to discard
any data not including all the effects of block and killing in each
phase reported below. The chosen simulation reproduces experi-
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Figure 1 Aplidine chemical structure.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1510–1517mental cell cycle percentages within 2% and experimental cell
counts within 10%. Notice that the method allows us to estimate
the percentage of cells blocked in G1 and G2M and the number
of dead cells, distinguishing between cells that have died when they
were blocked in G1 or in G2M.
As shown in Figure 3A, the simulation required the introduction
of a partial G2M block to reproduce the experimental data at
concentrations as low as 5 nM. Among the cells exiting from
G2M between 0 and 6 h (2.6% of the whole cell population per
hour in controls), the probability of being blocked ranged from
15% (5 nM) to 22% (30 nM) resulting in the 2.3–3.2% cells in
the G2M block at 6 h. According to the simulation, after 48 h
drug-washout, G2M blocked cells were not detectable (51%) using
410 nM Aplidine, due to either their death or exit from the block,
while at higher concentration blocked cells were detected up to
72 h despite a continuous loss (Figure 3A,B). Mortality in G2M
peaked around 24 h with any Aplidine concentration from 5 to
30 nM.
AG 1 block was suggested by the simulation, at any concentra-
tion starting from 24 h after drug-washout, even when the
observed per cent G1 was not increasing over time after treatment
with 30 nM Aplidine (Figure 3C,D). The percentage of G1 blocked
cells after treatment with the concentrations higher than 10 nM
increased from 24 to 48 h, indicating that even those cells that
entered G1 between 24 and 48 h were susceptible to arrest. A
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Figure 2 Effect of 1 h (A)o r2 4h( B) Aplidine exposure on cell growth
evaluated at different time intervals after treatment and drug-washout. Each
point is the mean of three replicates; bars represent the standard deviation.
Solid diamond=Aplidine 1 nM; solid circle=Aplidine 5 nM; solid triangle=
Aplidine 10 nM; open triangle=Aplidine 20 nM; open circle=Aplidine 30 nM.
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Figure 3 (A–C) Percentages of cells in G2M( A) and G1 (C) cell cycle
phases. The black columns indicate the percentage of blocked cells in G2M
or G1, as resulting from simulation of experimental cell cycle percentages
and absolute cell counts. (B–D) Percentage of cell cohort, from the overall
initial population, which have died during G2M( B)o rG 1 (D) block and
evaluated at different time intervals after drug-washout (simulation results).
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British Journal of Cancer (2002) 86(9), 1510–1517 ã 2002 Cancer Research UKlong-lasting continuous G1 block, with 20 and 30 nM Aplidine, was
suggested by the presence of G1 blocked cells at 72 h despite their
loss. A different balance between arrest and death resulted in a
different behaviour with lower concentrations: more blocked cells
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Figure 4 Effects of 1 h Aplidine exposure on the cell cycle phase distribution of Molt-4 cells evaluated at 0, 4, 8, 12, 24, 29, 36 and 48 h after drug-
washout. During the last 15 min 10 nM Aplidine treatment, 20 mM BrdUrd was added to the cells, then the cells were washed with PBS and drug-free
medium was provided. (A) Biparametric BrdUrd/DNA analysis of (a) control cells; and (b) Aplidine treated cells. (B) DNA histograms of (a) control cells
(whole population); (b) Aplidine treated cells (whole population); (c) BrdUrd-negative control cells; (d) BrdUrd-negative Aplidine treated cells; (e) BrdUrd-
positive control cells; and (f) BrdUrd-positive Aplidine treated cells. The data are representative of three independent replicates.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1510–1517were obtained with 5 (9%) than with 10 nM (5%) at 72 h, due to
the higher mortality with 10 nM. Although more cells died in G1
than in G2M, G1 lost cells were proportionally less than G2M lost
cells after correction for the amount of cells present in these
phases. For instance, with 20 nM, the number of cells that globally
(in the 0–72 h interval) died in G1 was double than in G2M, but
per cent G1 was on average four-fold per cent G2M and 29% cells
were blocked in G1 against 4% in G2Ma t7 2h .
A temporary S phase delay was observed with intermediate
doses; this effect became strong and persistent only at 30 nM Apli-
dine. No mortality effect was detected in S phase (data not shown).
Figure 4 shows the effects on the cell cycle phase distributions
caused by 1 h exposure with 10 nM Aplidine in Molt-4 cells eval-
uated by BrdUrd/DNA ﬂow cytometric analysis at different time
intervals after drug-washout. After Aplidine-washout, cells which
were in the S phase (BrdUrd positive cells) during drug treatment,
progressed through this phase of the cell cycle more slowly than
control cells. At 8 h the fraction of cells that started a new cell cycle
(G1 BrdUrd positive cell population) was higher in control (27%)
rather than Aplidine treated cells (8%). At 24 h and up to 48 h
after drug-washout the data are indicative of a G1 block, in agree-
ment with simulation studies.
Aplidine was found to delay those cells that were in the G1
phase (BrdUrd negative cells) during drug treatment, from entering
S phase. At 24 and up 48 h after Aplidine-washout the majority of
the BrdUrd negative cells were blocked in the G1 phase too.
ODC activity
As shown in Figure 5A, 1 h exposure to 10 or 20 nM Aplidine
caused an inhibition of ODC of 75%. The same percentage of inhi-
bition was observed after 24 h of exposure. Aplidine per se did not
affect ODC activity of a partially puriﬁed preparation, obtained by
centrifugation of the cell homogenate at 14000 r.p.m. for 20 min
in an Eppendorf microcentrifuge at 208C. This was shown by
adding directly the drug (20 nM Aplidine) to test tubes containing
all the components for ODC activity assay including the superna-
tant (about 150 mg of protein) (data not shown). At 24 h after
drug-washout we observed a persistent inhibitory effect of the Apli-
dine on ODC activity. However, control ODC activity was
stimulated by the addition of fresh medium (24+24).
In agreement with the decrease of ODC activity, we observed
that putrescine levels diminished in Aplidine treated cells at 1 h
(30 and 60% for Aplidine 10 and 20 nM respectively) and at
24 h (80% decrease) at both concentrations (Figure 5B). At 24 h
after drug-washout (1 or 24 h treatment plus 24 h drug-washout)
putrescine levels further decrease in Aplidine treated cells, while
the control cells showed a huge increase probably due to fresh
medium change that increased also ODC activity. Only spermidine
level decreased (60–80%) at 24 h after drug-washout in 24 h Apli-
dine treated cells. At the other times of treatment higher polyamine
(spermidine and spermine) levels were unaffected by Aplidine
(Figure 5B).
To evaluate if decreased levels of putrescine could be important
for the cytotoxic effect of Aplidine, 1 mM putrescine was added to
the cells 2 h before 1 h Aplidine treatment. Then the drug-contain-
ing medium was removed and fresh medium containing 1 mM
putrescine was added to the cells. Under these conditions the intra-
cellular levels of putrescine were 6.44 nmol mg
71 protein in
control cells, 16.8 nmol mg
71 protein putrescine pretreated
control cells, 4.7 nmol mg
71 protein Aplidine treated cells and
16.9 nmol mg
71 protein in Aplidine treated cells preincubated
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Figure 5 (A) Ornithine decarboxylase (ODC) activity evaluated after 1 and 24 h Aplidine treatment and at 24 h after drug-washout. The data are the
mean+s.e. of three independent experiments performed in duplicate. 1=1 h Aplidine treatment; 1+24=1 h Aplidine treatment+24 h drug-washout;
24+24=24 h Aplidine treatment+24 h drug-washout; solid square=control cells; open square=10 nM Aplidine; striped square=20 nM Aplidine. (B) Putres-
cine, spermidine and spermine determinations performed after 1 and 24 h Aplidine treatment and at 24 h after drug-washout. The data are the mean+s.e.
of three independent experiments performed in duplicate. 1=1 h treatment; 1+24=1 h treatment plus 24 h drug-washout; 24=24 h treatment;
24+24=24 h treatment plus 24 h drug-washout; solid square=control cells; open square=10 nM Aplidine; striped square=20 nM Aplidine.
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cine levels were comparable to that of control cells Aplidine was
equally cytotoxic indicating that the cytotoxicity was not related
to putrescine depletion (data not shown).
Macromolecular synthesis
DNA, RNA and protein synthesis were evaluated after 1, 4, 8 and
24 h Aplidine exposure in Molt-4 cells. One hour Aplidine treat-
ment at concentrations up to 50 nM did not cause a signiﬁcant
inhibition of DNA, RNA or protein synthesis. Inhibition of
DNA, RNA and protein synthesis were obtained only at higher
Aplidine concentrations (i.e. after 1 h with concentrations
4100 nM) and/or a time exposures (i.e. after 8 h with concentra-
tions 550 nM; data not shown).
Cell cycle related proteins
We then evaluated the expression of proteins that regulate cell-
cycle progression at the end of treatment with 10 nM Aplidine
and 4, 8 and 24 h after drug-washout by Western blot analysis.
As shown in Figure 6A, the protein levels of Cdk2, Cdc2 and
Cdk4, cyclin B and D1 remained constant at each time tested, with
only a decline in cyclin E levels observable at 24 h after drug-wash-
out. p16 levels were undetectable in Molt-4 lysates in agreement
with the previously reported deletion of this gene in this cell line
(Uchida et al, 1995).
The levels of p21, p53 and pRb, did not change under these
experimental conditions.
Cdk2 Kinase activity measured at the end of 1 h treatment with
10 nM Aplidine (time 0 h) and at 4 and 24 h after drug-washout
was not affected by drug treatment (Figure 6B). Cdk2 and cyclin
E protein levels did not change in Western blot analysis of immu-
noprecipitates.
Similarly, Aplidine did not inhibit Cdk2 activity in vitro using
recombinant Cdk2/cyclinE and Cdk2/cyclinA complexes (data not
shown)
Cell death
We investigated the mechanism of cell death induced by Aplidine
by using TdT-dUTP ﬂow cytometric analysis. One hour Aplidine
exposure already induced apoptosis in Molt-4 cells at 6 h after
drug-washout, and the fraction of apoptotic cells was dose and
time dependent (Figure 7). By using biparametric DNA/TdT-
dUTP ﬂow cytometric analysis we did not observe a speciﬁc cell
cycle phase dependency of the apoptotic cell death (data not
shown).
To evaluate if caspase 3 was involved in the induction of apop-
tosis we performed Western blotting analysis on the total protein
extract of Molt-4 cells treated for 1 h with 10 or 20 nM with Apli-
dine. The analysis was performed after drug treatment and at 6 and
24 h after drug-washout. As shown in Figure 8 we found that in
the 10 nM treated cells just after 1 h treatment caspase 3 was
cleaved into its 12 kDa activated form. At 6 and 24 h after drug-
washout the activation of caspase 3 with the appearance of 12
and 20 kDa activated forms was clearly evident. Bax levels were
not changed after treatment indicating that the apoptotic pathway
was bax independent.
DISCUSSION
The present study shows that Aplidine causes profound perturba-
tions of the cell cycle as well as apoptosis in the human
lymphoblastic leukaemia cell line Molt-4 at very low concentrations
(nM range).
The concentrations (20 nM) which produced signiﬁcant cell
death can be achieved for several hours in the plasma of patients
receiving Aplidine doses ranging from 3750 to 6000 mgm
72 given
as a 24 h infusion (Paz-Ares et al, 2000; Armand et al, 2001).
A new ﬁnding, reported here for the ﬁrst time is that Aplidine
not only induces a G1 arrest (Crampton et al, 1984), but also a
G2 blockade. It is interesting to note that the block in G2 is prob-
ably relevant as a large proportion of cells blocked in this phase
subsequently undergo cell death. Whatever the mechanism of
action of Aplidine, it acts very quickly and a prolonged exposure
time (e.g. from 15 min to 1 or 24 h) does not increase the effects
of the drug proportionally.
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Figure 6 (A) Immunoblot analysis of Cdk2, Cdc2, Cdk4, cyclin B1, D1
and E, p21, p16, p53, and pRb expression in Molt-4 cells treated for 1 h
with 10 nM Aplidine (three independent replicates). Molt-4 extracts were
collected before and after treatment and, at 4, 8, 24 h after drug washout.
One hundred mg of protein extracted from cells were immunoblotted with
speciﬁc antibodies as described in Materials and methods. (B) (a) Histone
H1 phosphorylation in Molt-4 cells lysates immunoprecipitated with Cdk2
antibodies. Cells were exposed for 1 h to 10 nM Aplidine (0 h) and then
incubated in drug free medium (4 and 24 h after drug-washout) (three
independent replicates). (b) Western blot analysis of Cdk2 and cyclin E
in Cdk2 immunoprecipitates (three independent replicates).
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synthesis as suggested by the fact that the structural analogue
didemnim inhibits the l a-elongation factor (Crews et al, 1994).
Our data do not support the contention that protein synthesis is
the primary mechanism by which Aplidine is cytotoxic. In fact,
there are clear perturbations of the cell cycle at drug concentrations
and time intervals in which no major decrease in the total synthesis
of proteins or of other macromolecules occurs. For example, a
concentration of 10 nM Aplidine for 1 h caused no detectable inhi-
bition of total proteins, RNA or DNA synthesis but did cause
marked cell cycle perturbations and cytotoxicity.
Another hypothesised mechanism of action of Aplidine was the
inhibition of ODC (Urdiales et al, 1996). Intracellular polyamines,
spermidine and spermine and their precursor putrescine are
intimately involved in cell growth and proliferation. Intracellular
polyamine levels are highly regulated and are primarily dependent
upon the activity of ODC, that catalyses the ﬁrst and rate-limiting
step in polyamine biosynthesis. It has also been proposed that there
exists polyamine-dependent restriction points during G0–G 1 tran-
sition and G1 phase progression of the cell cycle (Harada and
Morris, 1981; Seidenfeld et al, 1986; Charollais and Mester,
1988). The present study conﬁrms that in cells treated with Apli-
dine there is a marked inhibition of ODC activity, an effect that
could not be reproduced in vitro on the partially puriﬁed enzyme.
The inhibition of ODC caused a strong decrease in putrescine
levels which might be a relevant event triggering cell cycle pertur-
bations and apoptosis. However, our data tend to exclude that
depletion of putrescines plays a major role in the biological effects
of Aplidine. In fact, the addition of putrescine at concentrations
that increased intracellular putrescine concentrations comparable
or even higher than that of controls did not signiﬁcantly reduce
cell cycle perturbations or the cytotoxicity of Aplidine.
Although further studies are required on this point it appears
that the cell cycle perturbations observed after Aplidine treatment
are not due to an effect on the cyclin dependent kinases that regu-
late the cell cycle progression. It appears more likely that the cell
cycle block in G1 or in G2 is related to activation of cell cycle check
points.
No information on the mechanism of cell cycle arrest is available
but we can exclude the possibility that p53 is involved as Molt-4
cells do not express wt p53.
In addition, similar results have been obtained in other acute
lymphoblastic leukaemia (ALL) lines with mutated p53 such as
K562 and on fresh ALL cells grown on stromal feeder layer (Erba
et al, in preparation).
In conclusion, although the data reported do not provide an
explanation for the biological effects of Aplidine they indicate that
this peptide acts by a mechanism different from that of other
known anticancer drugs. The rapid induction of apoptosis in
human leukaemia cells at concentrations even lower than those
that can be achieved and maintained for many hours in plasma
of patients receiving the drug at tolerable dose, provides a rational
to undertake clinical investigation wit this drug in human leukae-
mia.
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Figure 7 Detection of apoptosis. Cells were treated with different concentrations of Aplidine and the biparametric FSC/TdT-dUTP ﬂow cytometric
analysis were performed after 6, 24, 48 and 72 h after drug-washout. The percentage of apoptotic cells obtained at different time intervals and the ﬂow
cytometric FSC/TdT-dUTP analysis performed at 72 h after drug-washout are reported.
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Figure 8 Western blot analysis of caspase 3 and Bax in Molt-4 cells
treated for 1 h with 0, 10 or 20 nM Aplidine and evaluated at different time
intervals after drug-washout.
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